Evaluation of efficacy of buserelin plus nilutamide in Mexican Male patients with advanced prostate cancer

Abstract

Introduction

In recent years, total androgen blockade therapy for advanced prostate cancer has been a reasonable option to castration due to the discovery and development of new pharmacologic agents. In this study, our aim was to evaluate the efficacy of the combined treatment of nilutamide plus buserelin and to describe the occurrence of adverse events associated with this treatment.

Material and methods

A descriptive, prospective study was conducted. Patients with advanced prostate cancer receiving nilutamide plus buserelin were evaluated at 3, 6, and 9 months. The primary endpoint was the reduction of serum levels of prostate-specific antigen (PSA).

Results

One hundred and four patients were included in the study, but only 67 patients had complete information and thus were evaluated in the efficacy analysis: 65 (97.0%) achieved a 50% reduction in PSA level, compared with the baseline value, and 2 patients achieved a decrease <10 ng/ml. The combination therapy was well tolerated, given that only 7 patients (6.7%) presented with mild adverse events that did not require treatment suspension or other specific maneuvers.

Conclusions

Treatment with nilutamide plus buserelin appears to be safe and effective in controlling tumor activity in advanced prostate cancer patients.